On July 23 the FDA held a public meeting concerning the “extended release†(aka – OxyContin) products under the guise of creating new “safety guidelinesâ€. The guidelines were presented under the auspices of REMS – Risk Evaluation and Mitigation Strategy. REMS was initiated in 2007 to bring greater information to the public if a “DRUG’S BENEFITS OUTWEIGH ITS RISKSâ€...
© 2011 - Prescription Addiction Radio